Tesamorelin Half-Life Is Measured in Minutes

Tesamorelin half-life is measured in minutes, not hours. Older 2 mg data put it at 26 minutes in healthy adults and 38 minutes in adults with HIV. The current Egrifta WR label reports 11 minutes after one 1.28 mg dose in healthy adults. In plain terms, the medicine itself leaves the blood quickly, but the growth-hormone signal it starts can continue after the drug is mostly gone.

That is why a short half-life doesn't mean a short effect. It also doesn't provide a personal injection schedule.

What the tesamorelin half-life numbers mean

Half-life means the time it takes the body to remove half of a dose from the blood. After another half-life, half of what remains is removed again. A common rule of thumb says the blood level is about 97% lower after five half-lives, but that isn't a guarantee that every trace is gone or that a lab test cannot find it.

Two tesamorelin estimates circulate because they come from different studies:

These aren't three interchangeable answers. The dose, formulation, population and timing of the blood samples differed. Egrifta WR's label also says WR and SV aren't substitutable. For the current WR product, 11 minutes is the label number; 26–38 minutes remains the familiar estimate from the older formulation and study setup.

A population analysis of 38 participants found that tesamorelin's path through the blood could be described with a simple absorption-and-clearance model. Within that small study, age, body size, race and HIV status did not identify clinically useful predictors of clearance. So body weight cannot turn these averages into a reliable personal countdown.

Why the effect can outlast the drug

Tesamorelin copies growth hormone-releasing hormone, or GHRH, a natural message from the brain. It rings the pituitary—the small gland beneath the brain—and the pituitary releases growth hormone in pulses. That, in turn, raises insulin-like growth factor 1, or IGF-1, a longer-running blood marker of growth-hormone activity. What tesamorelin does explains that chain in more detail.

Think of the medicine as a finger pressing a doorbell. The finger moves away quickly; the signal has already traveled inside. Half-life times the finger, not everything that happens after the bell rings.

In a small 2011 physiology study, 13 men received the older 2 mg formulation once daily for 14 days. Researchers still measured changes in overnight growth-hormone release beginning about eight hours after the final shot, and IGF-1 was higher when measured about 20 hours after it. Two weeks after treatment stopped, IGF-1 was no longer significantly different from baseline. The study authors were careful: they said the reason a brief exposure produced a longer signal was not fully known.

A tesamorelin-and-ipamorelin blend doesn't have one meaningful shared half-life. Ipamorelin is a different signal with its own behavior, and compounded formulations vary by pharmacy and prescription. The tesamorelin and ipamorelin comparison is the better place to understand why a provider might consider both; the tesamorelin number alone cannot set the blend's timing.

Why trials used tesamorelin once daily

Once-daily use in published trials did not keep tesamorelin at a steady level all day. It repeated a short signal on a regular schedule. A pooled 2010 analysis of two phase 3 trials followed 806 adults with HIV and excess abdominal fat for 26 weeks, with a further 26-week extension. The trial protocol used daily treatment and tracked IGF-1 and body composition over months, not hour by hour.

That distinction matters. A dosing interval comes from the whole clinical program: the signal, repeated exposure, benefits, side effects and monitoring all count. It cannot be calculated by multiplying half-life alone. Tesamorelin dosing covers how published schedules inform a provider's decision without turning them into instructions.

As of September 6, 2026, the day this article was written, a meta-analysis published July 31 pooled four randomized trials with 909 adults and found IGF-1 averaged about 109 ng/mL higher with tesamorelin than placebo. The authors rated the IGF-1 evidence as moderate certainty. A separate trial protocol published July 8 plans to use Egrifta WR daily for 24 weeks and check IGF-1 at weeks 2, 12 and 24; it has no outcome results yet. Neither paper changes the half-life. Both show why researchers follow the downstream marker over weeks.

What a provider monitors

IGF-1 is the main marker because it shows the biological signal that remains after tesamorelin itself has faded from the blood. The current label says to monitor it during treatment and to consider stopping when elevations remain above 3 SDS, meaning more than three standard deviations above the age-adjusted average, especially when the clinical response is limited.

The numbers are worth making concrete. In the label's trials, about 1 in 3 participants—36%—had IGF-1 above 3 SDS after 26 weeks. Among those who continued to 52 weeks, 23% were above that mark. The label also calls for blood-glucose monitoring because tesamorelin can affect glucose tolerance. A provider weighs those labs alongside symptoms, medical history and whether the intended response is actually happening.

This is also why feeling that a shot has “worn off” isn't a sound reason to change timing. The molecule may be gone while the hormone signal remains active. Questions about swelling, joint discomfort, tingling or injection-site reactions belong with the prescriber; tesamorelin side effects explains what has been reported.

Brand and compounded tesamorelin are different

Tesamorelin through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Egrifta WR's reviewed indication is narrower than many online conversations suggest: reducing excess abdominal fat in adults with HIV and lipodystrophy, which means abnormal fat distribution. It is not labeled as general weight management.

The Egrifta data help explain the molecule, but they do not replace the directions or monitoring plan attached to a compounded prescription. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.

At Promise, a licensed provider reviews every request and not everyone qualifies. If tesamorelin is prescribed, the provider sets the dose, timing and lab follow-up for that person.